LEXX (Lexaria Bioscience) Current Deferred Taxes Liabilities: $0.00 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LEXX Lexaria Bioscience Corp LEXX
36 GF Score
Price $11.28
GF Value $5.38
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Lexaria Bioscience Current Deferred Taxes Liabilities?

Lexaria Bioscience LEXX +8.78% 36 Current Deferred Taxes Liabilities is $0.00 Mil as of May. 2026. GuruFocus rates LEXX with a GF Score™ of 36/100 and a GF Value™ of $5.38 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Lexaria Bioscience's current deferred tax liabilities for the quarter that ended in May. 2026 was $0.00 Mil.

Lexaria Bioscience Current Deferred Taxes Liabilities Related Terms

Lexaria Bioscience Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for Lexaria Bioscience's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexaria Bioscience Current Deferred Taxes Liabilities Chart

Lexaria Bioscience Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Lexaria Bioscience Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LEXX
36GF Score
Lexaria Bioscience Corp LEXX
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of $0.00 Mil mean?
Lexaria Bioscience (LEXX) has a Current Deferred Taxes Liabilities of $0.00 Mil as of May. 2026. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Lexaria Bioscience and its competitors.
Is Lexaria Bioscience's Current Deferred Taxes Liabilities too high?
Lexaria Bioscience's current Current Deferred Taxes Liabilities is $0.00 Mil. Overall, Lexaria Bioscience has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's Current Deferred Taxes Liabilities compare to TPST and LPCN?
Lexaria Bioscience's Current Deferred Taxes Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Biotechnology company?
A good Current Deferred Taxes Liabilities depends on the Biotechnology industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Lexaria Bioscience and its competitors. Lexaria Bioscience's current Current Deferred Taxes Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.38, compared to a current price of $11.28 — trading 109.7% above its estimated fair value. The current Current Deferred Taxes Liabilities is $0.00 Mil. Lexaria Bioscience's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current Current Deferred Taxes Liabilities is $0.00 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lexaria Bioscience (LEXX) Overvalued in 2026?

Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be overvalued. The current stock price of $11.28 is trading 109.7% above its estimated GF Value™ of $5.38. GuruFocus considers Lexaria Bioscience to be Significantly Overvalued.

Key valuation signals for LEXX:

  • Current Deferred Taxes Liabilities: $0.00 Mil
  • GF Value™: $5.38 vs. price of $11.28 (109.7% above fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lexaria Bioscience Business Description

Address 740 McCurdy Road, No. 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
36GF Score

Get the complete analysis for LEXX

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.28
Price
$5.38
GF Value